Orthopedic Implant Contracting, Round II
For suppliers, the first generation of orthopedic implant contracts was disappointing, to say the least. Hospital purchasing groups disagree--but their second generation contracts subtly address supplier dissatisfactions. Still, in an era of shifting market leaders and a consolidating industry, will contracting ever really catch on?
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.